AtriCure (ATRC) Reports In-Line Q3 EPS; Guides FY15 Revenue Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
AtriCure Reports Third Quarter 2015 Financial Results
October 27, 2015 4:01 PM EDTRevenue of $31.4 million up 17.8% as reported, 20.6% constant currency U.S. sales of $24.7 million up 23.0% International sales of $6.7 million up 2.1% as reported, 13.2% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced third quarter 2015 financial results.
We are pleased with our performance in the third quarter and excited about our prospects for sustained growth, said Mike Carrel, President and Chief Executive... More
